April 1, 2019Diabetes Obesity and Metabolism
Effects of sodium glucose cotransporter type 2 inhibitors on heart failure
Why the study?
Patients with T2D remain at high risk for HF despite traditional risk factor control, and prior glucose-lowering drugs lacked HF benefit, highlighting the need for effective prevention and treatment strategies.
Do SGLT-2 inhibitors reduce the risk of cardiovascular death or heart failure hospitalization in patients with type 2 diabetes?
Population
Patients with T2D enrolled across three CVOTs (EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58)
Comparison
SGLT-2i vs comparator
Design
Meta-analysis of three randomized CV outcomes trials
Authors
Discussion
Loading...
Member takes
Implication
Supports SGLT-2i for HF risk reduction in T2D; leaves open optimal use and generalizability beyond included trials.
Structured PICO
Do SGLT-2 inhibitors reduce the risk of cardiovascular death or heart failure hospitalization in patients with type 2 diabetes?
P
Population
Patients with type 2 diabetes (T2D) from three cardiovascular outcomes trials (EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58) with varying ASCVD risk, primarily without established heart failure.
I
Intervention
Sodium glucose cotransporter type 2 inhibitors (SGLT-2i)
O
Outcome
Composite of cardiovascular death or hospitalization for heart failurecomposite
SGLT-2 inhibitors demonstrate robust and consistent benefits in reducing heart failure hospitalizations and cardiovascular death in patients with type 2 diabetes, highlighting their role in heart failure prevention.
Limitations
- Only a small proportion of patients with established HF were enrolled in the trials, representing primarily a HF prevention signal.
Cite This Study
Nassif et al. (2019) studied this question.